Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes - Test2 - elhamkhani - TriplyDB

Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes

Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes

http://www.wikidata.org/entity/Q33648910

about

HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads HIV-1 VACCINES. HIV-1 neutralizing antibodies induced by native-like envelope trimers HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies.Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits.Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies Structure-based vaccine design in HIV: blind men and the elephant?Binding interactions between soluble HIV envelope glycoproteins and quaternary-structure-specific monoclonal antibodies PG9 and PG16.The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques.Hyperimmune bovine colostrum as a low-cost, large-scale source of antibodies with broad neutralizing activity for HIV-1 envelope with potential use in microbicides.HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens.Improvement of antibody responses by HIV envelope DNA and protein co-immunization.Native-like Env trimers as a platform for HIV-1 vaccine design.Assessment of mucosal immunity to HIV-1.Neutralizing antibodies and control of HIV: moves and countermoves.

P2860

Q21131399-9A743413-4541-4E5D-A12B-118489663C11 Q28647225-F99E495D-CBB8-4F93-815C-37E2B1F5FD30 Q33753573-5AC512C2-F506-434D-AECE-612F7AE94CF0 Q34539819-8D26746D-E6B4-4A30-B4FE-E8E981C9F4AC Q34594513-0D9D34E1-464F-418A-B835-CBE4F08834CC Q34982715-C198B654-64EA-4546-8350-94436DB19DE2 Q34987048-1CD2D1C8-32D1-4531-A9FB-B5592AE95B81 Q35077716-C48F33D0-2FAE-45BF-9510-75BDBCE2BDF5 Q35644971-459D19B9-8DE6-4D93-8ED8-B6B4670486D1 Q35821368-F8F377A1-55BD-4D98-BF46-3653880F5C37 Q36171536-89680750-648B-4A1F-9CA6-B345973B9B88 Q36252656-7A710A9C-7FEF-4347-B961-38C8940D96DE Q36702114-BFAD4E73-7F4F-4C22-923C-C6F991029822 Q37588371-AC66C288-90CA-4865-82FB-3B0E5E10356D Q37633417-5B9C86F7-559F-464E-969E-FED2A9DDCBA9 Q37724856-D83B8216-D335-4A16-A1A7-4B0511E2855F Q37971867-92140E38-19F1-471D-A8CC-05653BB6A8D9

P2860

Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes

http://www.wikidata.org/entity/Q33648910

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Comparative immunogenicity of ...... served neutralization epitopes

@ast

Comparative immunogenicity of ...... served neutralization epitopes

@en

type

label

Comparative immunogenicity of ...... served neutralization epitopes

@ast

Comparative immunogenicity of ...... served neutralization epitopes

@en

prefLabel

Comparative immunogenicity of ...... served neutralization epitopes

@ast

Comparative immunogenicity of ...... served neutralization epitopes

@en

P1433

Q33648910-D9620823-FD88-49F0-9FD4-FFDD44B6C4E6

P1476

Q33648910-AE77C1F0-A9D7-4748-8684-7DE16CD4D194

P2093

Q33648910-1FE1DCF6-681C-4BB6-B08C-80A87CA05853

Q33648910-21C1254F-7747-4903-B8BA-8724CF74592E

Q33648910-456FBE34-0E96-455B-9F7E-0C9DD7E32B3F

Q33648910-646BA1D8-9C28-4895-869D-042C43C25797

Q33648910-6C6F7949-CADA-45D4-9C3E-B4B558321238

Q33648910-8EE8DCF5-C0D3-4B27-B5BB-C970F59ED7B5

Q33648910-B770BDF0-9824-4347-AC4D-F3CF7D907946

Q33648910-D6BDA470-022E-4308-B592-625A62E807A4

Q33648910-DFDED366-A994-4039-902A-96A772222DAC

P2860

Q33648910-00C6C331-8699-4E38-A26F-EEAEB95D4BEB

Q33648910-04B0821F-65C5-4437-B810-4DD6B49FCA96

Q33648910-0DE391F8-CE13-4EF5-BCD0-A4782CBA7FAD

Q33648910-11CCCB5A-F176-48B5-88B8-3586B8D6A908

Q33648910-1325C574-03DD-4ECF-9B59-5F77F0D999C2

Q33648910-1871322D-EECE-4659-BFEA-65AE44E70AF7

Q33648910-264298B9-A5D0-4A43-B183-F384F139B516

Q33648910-2C864BC0-1EC4-478D-B4EB-CA1D4D3701E1

Q33648910-31DE0DA7-AF7D-4227-A8ED-918D38563136

Q33648910-3608D662-98C8-4753-B9DA-A5E3A00EACFF

P304

Q33648910-9742D18B-CE79-4996-B424-3FAA552D54AF

P31

Q33648910-6EAEDC56-CAC7-45A0-8676-11D2D4298939

P356

Q33648910-D9331786-1878-4813-AB89-ADAF9813733D

P433

Q33648910-ADF7966F-38FF-4B9B-9410-13AEB42E6468

P478

Q33648910-049A4BEE-D6C6-4067-BA47-6935F9157B24

P50

Q33648910-209A9E72-9A87-4D75-A404-740A19BE1A87

P577

Q33648910-CDB2CE7A-7AFF-492A-A03E-4168E7588F9F

P698

Q33648910-E3E8BC4C-4D10-4471-A352-D2C47C209411

P932

Q33648910-3E843D44-070C-4DEE-9195-B1AC5F7B3580

P356

P1433

Journal of Virology

P1476

Comparative immunogenicity of ...... served neutralization epitopes

@en

P2093

Brad Cleveland

http://www.w3.org/2001/XMLSchema#string

Catherine A Blish

http://www.w3.org/2001/XMLSchema#string

D Noah Sather

http://www.w3.org/2001/XMLSchema#string

George Sellhorn

http://www.w3.org/2001/XMLSchema#string

Indresh Srivastava

http://www.w3.org/2001/XMLSchema#string

Leonidas Stamatatos

http://www.w3.org/2001/XMLSchema#string

Shiu-lok Hu

http://www.w3.org/2001/XMLSchema#string

Susan W Barnett

http://www.w3.org/2001/XMLSchema#string

Yide Sun

http://www.w3.org/2001/XMLSchema#string

P2860

Codon usage limitation in the expression of HIV-1 envelope glycoprotein

Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response

Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B

Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope

Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target

Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies

Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41.

B cell recognition of the conserved HIV-1 co-receptor binding site is altered by endogenous primate CD4.

Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

P304

2573-2584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/JVI.01687-09

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

84

http://www.w3.org/2001/XMLSchema#string

P50

Julie Overbaugh

P577

2009-12-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20015987

http://www.w3.org/2001/XMLSchema#string

P932

2820908

http://www.w3.org/2001/XMLSchema#string